Neurocrine
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.
NBIX Key Statistics
Stock Snapshot
With a market cap of 14.51B, Neurocrine(NBIX) trades at $141.50. The stock has a price-to-earnings ratio of 20.99.
On 2026-10-23, Neurocrine(NBIX) stock moved within a range of $140.90 to $143.83. With shares now at $141.50, the stock is trading +0.4% above its intraday low and -1.6% below the session's peak.
Trading volume for Neurocrine(NBIX) stock has reached 1.03M, versus its average volume of 1.21M.
Over the past 52 weeks, Neurocrine(NBIX) stock has traded between a high of $186.12 and a low of $122.14.
Over the past 52 weeks, Neurocrine(NBIX) stock has traded between a high of $186.12 and a low of $122.14.
NBIX News
has delivered steady long term gains for shareholders, and fresh clinical updates keep attention on what the pipeline might mean for profits. The open question...
Neurocrine (NBIX) announced the initiation of its Phase 2 clinical study of investigational compound NBI-1117567 in adults with mild to moderate Alzheimer’s dis...
Analyst ratings
87%
of 31 ratingsPeople also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.